| pubmed-article:19914548 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:19914548 | lifeskim:mentions | umls-concept:C0008976 | lld:lifeskim |
| pubmed-article:19914548 | lifeskim:mentions | umls-concept:C0549177 | lld:lifeskim |
| pubmed-article:19914548 | lifeskim:mentions | umls-concept:C1704644 | lld:lifeskim |
| pubmed-article:19914548 | lifeskim:mentions | umls-concept:C1519814 | lld:lifeskim |
| pubmed-article:19914548 | pubmed:dateCreated | 2009-11-16 | lld:pubmed |
| pubmed-article:19914548 | pubmed:abstractText | There is accumulating data on the clinical benefit of aromatase inhibitors in the adjuvant treatment of early-stage breast cancer in postmenopausal women. The Breast International Group (BIG) 1-98 study is a randomized, phase 3, double-blind trial comparing four adjuvant endocrine treatments of 5 years duration in postmenopausal women with hormone-receptor-positive breast cancer: letrozole or tamoxifen monotherapy, sequential treatment with tamoxifen followed by letrozole, or vice versa. This article summarizes data presented at the 2009 St. Gallen early breast cancer conference: an update on the monotherapy arms of the BIG 1-98 study, and results from the sequential treatment arms. Implications for daily practice from BIG 1-98 and from other adjuvant trials will be discussed. | lld:pubmed |
| pubmed-article:19914548 | pubmed:language | eng | lld:pubmed |
| pubmed-article:19914548 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19914548 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:19914548 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19914548 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19914548 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19914548 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19914548 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19914548 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19914548 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19914548 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19914548 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:19914548 | pubmed:month | Oct | lld:pubmed |
| pubmed-article:19914548 | pubmed:issn | 1532-3080 | lld:pubmed |
| pubmed-article:19914548 | pubmed:author | pubmed-author:JoergerMarkus... | lld:pubmed |
| pubmed-article:19914548 | pubmed:author | pubmed-author:ThürlimannBea... | lld:pubmed |
| pubmed-article:19914548 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:19914548 | pubmed:volume | 18 Suppl 3 | lld:pubmed |
| pubmed-article:19914548 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:19914548 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:19914548 | pubmed:pagination | S78-82 | lld:pubmed |
| pubmed-article:19914548 | pubmed:meshHeading | pubmed-meshheading:19914548... | lld:pubmed |
| pubmed-article:19914548 | pubmed:meshHeading | pubmed-meshheading:19914548... | lld:pubmed |
| pubmed-article:19914548 | pubmed:meshHeading | pubmed-meshheading:19914548... | lld:pubmed |
| pubmed-article:19914548 | pubmed:meshHeading | pubmed-meshheading:19914548... | lld:pubmed |
| pubmed-article:19914548 | pubmed:meshHeading | pubmed-meshheading:19914548... | lld:pubmed |
| pubmed-article:19914548 | pubmed:meshHeading | pubmed-meshheading:19914548... | lld:pubmed |
| pubmed-article:19914548 | pubmed:meshHeading | pubmed-meshheading:19914548... | lld:pubmed |
| pubmed-article:19914548 | pubmed:meshHeading | pubmed-meshheading:19914548... | lld:pubmed |
| pubmed-article:19914548 | pubmed:meshHeading | pubmed-meshheading:19914548... | lld:pubmed |
| pubmed-article:19914548 | pubmed:meshHeading | pubmed-meshheading:19914548... | lld:pubmed |
| pubmed-article:19914548 | pubmed:meshHeading | pubmed-meshheading:19914548... | lld:pubmed |
| pubmed-article:19914548 | pubmed:meshHeading | pubmed-meshheading:19914548... | lld:pubmed |
| pubmed-article:19914548 | pubmed:meshHeading | pubmed-meshheading:19914548... | lld:pubmed |
| pubmed-article:19914548 | pubmed:meshHeading | pubmed-meshheading:19914548... | lld:pubmed |
| pubmed-article:19914548 | pubmed:meshHeading | pubmed-meshheading:19914548... | lld:pubmed |
| pubmed-article:19914548 | pubmed:meshHeading | pubmed-meshheading:19914548... | lld:pubmed |
| pubmed-article:19914548 | pubmed:meshHeading | pubmed-meshheading:19914548... | lld:pubmed |
| pubmed-article:19914548 | pubmed:year | 2009 | lld:pubmed |
| pubmed-article:19914548 | pubmed:articleTitle | Update of the BIG 1-98 Trial: where do we stand? | lld:pubmed |
| pubmed-article:19914548 | pubmed:affiliation | Breast Center, Cantonal Hospital, St. Gallen, Switzerland. | lld:pubmed |
| pubmed-article:19914548 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:19914548 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:19914548 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:19914548 | pubmed:publicationType | Multicenter Study | lld:pubmed |
